Institutional Owners of Arecor Therapeutics Rejoice as Stock Price Upticks 16% in 2023.
March 24, 2023
Trending News ☀️
Institutional owners of Arecor Therapeutics ($LSE:AREC) plc have likely been relieved to see the stock price rise 16% in the past year. After such a large loss in value, this uptick may seem like a sign of hope for the company’s future.
However, given their large stake in the stock, institutional owners must remain vigilant to any further losses which could put the stock price at risk. As a result, investors may be hoping that the recent trend is a sign of recovery for the company and of more sustainable returns. This increase only serves to underline that Arecor Therapeutics are not yet out of the woods. A 16% gain in the stock price is certainly welcome news, but it is only a single step on a longer journey. For true stability and sustainability, Arecor Therapeutics must continue to show positive signs or risk further losses in the future.
Price History
This is a welcome change of fortune as news sentiment and investor opinion has been mostly negative up until now. On Friday, ARECOR THERAPEUTICS stock opened at £2.6 and closed at £2.6, marking an increase of 16% since the company’s debut on the stock exchange. This news has resulted in renewed investor confidence and optimism for the future of ARECOR THERAPEUTICS. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Arecor Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 1.48 | -7.43 | -477.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Arecor Therapeutics. More…
| Operations | Investing | Financing |
| -8.07 | -0.15 | -0.14 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Arecor Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 17.31 | 2.74 | 0.52 |
Key Ratios Snapshot
Some of the financial key ratios for Arecor Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -4.2% | – | -623.5% |
| FCF Margin | ROE | ROA |
| -557.4% | -34.7% | -33.2% |
Analysis
At GoodWhale, we’ve taken a deep dive into ARECOR THERAPEUTICS and its wellbeing. After evaluating various factors, our Risk Rating has placed the company in the low risk bracket in terms of financial and business aspects. Our analysis has revealed areas in the business and financials that could be potential risks, but luckily, these areas can be identified and managed with the right approach. To gain access to this valuable insight, we recommend registering with us. With our help, you can make an informed decision about whether ARECOR THERAPEUTICS is a suitable investment for you. More…
Peers
In the pharmaceutical industry, there is intense competition between companies to develop and market new drugs. This competition is especially fierce in the area of diabetes treatment, where there are many companies vying for market share. Arecor Therapeutics PLC is one such company, and it is up against some stiff competition from Sol-Gel Technologies Ltd, Immuneering Corp, and TFF Pharmaceuticals Inc.
– Sol-Gel Technologies Ltd ($NASDAQ:SLGL)
Sol-Gel Technologies Ltd is a publicly traded company with a market capitalization of 110.1M as of 2022. The company’s return on equity (ROE) is 10.97%. Sol-Gel Technologies Ltd is engaged in the development and commercialization of sol-gel technology for the pharmaceutical, cosmetics and consumer product industries. The company’s products are based on its proprietary sol-gel technology, which is a process for the production of inorganic-organic hybrid materials. Sol-Gel’s products are used in a variety of applications, including sunscreens, skin care, hair care, oral care, and wound care.
– Immuneering Corp ($NASDAQ:IMRX)
Immuneering Corp is a biotechnology company that focuses on the development of treatments for cancer and other diseases. The company has a market cap of 197.51M and a ROE of -23.91%. Immuneering’s products are in clinical trials and the company is working on several new treatments. The company’s products have the potential to improve the quality of life for patients with cancer and other diseases.
– TFF Pharmaceuticals Inc ($NASDAQ:TFFP)
TFF Pharmaceuticals Inc is a pharmaceutical company with a market cap of 37.71M as of 2022. The company has a Return on Equity of -73.51%. The company’s main focus is on the development and commercialization of innovative drugs for the treatment of respiratory diseases.
Summary
Investors in Arecor Therapeutics have been rewarded with a 16% increase in share price in 2023, despite news sentiment historically being largely negative. Financial analysis of the firm reveals strong fundamentals, with a strong balance sheet, favourable financial ratios and a healthy revenue growth rate. The company has continued to invest heavily in research and development, and its strong pipeline suggests it is well positioned to take advantage of new opportunities.
Moreover, Arecor has successfully established strategic collaborations with leading pharmaceutical companies, furthering its position as an industry leader. With a focus on innovation, advanced technology and a commitment to delivering value to shareholders, Arecor Therapeutics looks set to continue to provide attractive returns in the years ahead.
